1 – 5 of 12
- show: 5
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
DDR1/2 enhance KIT activation and imatinib resistance of primary and secondary KIT mutants in gastrointestinal stromal tumors
(
- Contribution to journal › Article
- 2020
-
Mark
Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
(
- Contribution to journal › Article
- 2019
-
Mark
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
(
- Contribution to journal › Article
- 2018
-
Mark
Role of ZNF224 in c-Myc repression and imatinib responsiveness in chronic myeloid leukemia
(
- Contribution to journal › Article
-
Mark
A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation
(
- Contribution to journal › Article